SecurityUBX / Unity Biotechnology, Inc. (91381U101)
Institutional Owners38
Institutional Shares9,310,206 - 22.00%
Common Shares Outstanding42,314,738 shares (as of 2018-06-30)
Institutional Value$ 138,652,000 USD

Institutional Stock Ownership and Shareholders

Unity Biotechnology, Inc. (NASDAQ:UBX) has 38 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9,310,206 shares. Largest shareholders include Baillie Gifford & Co, EcoR1 Capital, LLC, Partner Fund Management, L.P., NF Trinity Capital (Hong Kong) Ltd, Goldman Sachs Group Inc, Partner Investment Management, L.P., Redmile Group, LLC, BlackRock Inc., Capital World Investors, and Artal Group S.A..
Unity Biotechnology, Inc. (NASDAQ:UBX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-08-13 13F-HR Laurion Capital Management LP 127,949 1,927
2018-08-14 13F-HR VANGUARD GROUP INC 112,532 1,695
2018-08-07 13F-HR Catalyst Capital Advisors LLC 476 7
2018-08-07 13F-HR NF Trinity Capital (Hong Kong) Ltd 608,060 9,157
2018-09-18 13F-HR/A NORTHERN TRUST CORP 54,651 823
2018-08-14 13F-HR UBS Group AG 8,111 122
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 899 13
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 535,686 8,068
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 36 1
2018-08-14 13F-HR BARCLAYS PLC 1,568 24
2018-08-10 13F-HR Legal & General Group Plc 748 11
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 56,287 847
2018-07-31 13F-HR GILDER GAGNON HOWE & CO LLC 20,000 301
2018-08-14 13F-HR Redmile Group, LLC 250,400 3,771
2018-08-03 13F-HR Dean Capital Investments Management, Llc 36,036 543
2018-08-09 13F-HR BlackRock Inc. 230,935 3,478
2018-08-14 13F-HR Capital World Investors 219,489 3,306
2018-08-14 13F-HR Alyeska Investment Group, L.P. 75,883 1,143
2018-08-14 13F-HR Partner Investment Management, L.P. 308,764 4,079
2018-08-14 13F-HR JP Morgan Chase & Co 1,025 15
2018-08-14 13F-HR EcoR1 Capital, LLC 1,680,644 25,310
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 818 12
2018-08-14 13F-HR STATE STREET CORP 40,100 604
2018-08-14 13F-HR MORGAN STANLEY 44,642 672
2018-08-10 13F-HR CITIGROUP INC 726 11
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 15,217 230
2018-08-14 13F-HR ROYAL BANK OF CANADA 822 12
2018-08-10 13F-HR Artal Group S.A. 200,000 3,012
2018-08-06 13F-HR STRS OHIO 1,500 22
2018-08-14 13F-HR DEUTSCHE BANK AG\ 8,041 120
2018-08-14 13F-HR Partner Fund Management, L.P. 826,352 11,458
2018-08-13 13F-HR Ameritas Investment Partners, Inc. 415 6
2018-07-17 13F-HR BAILLIE GIFFORD & CO 3,803,014 57,274

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Not Just Pocket Change: China's Hillhouse Capital's New Fund Has $10.6 Billion to Invest

2018-09-20 biospace
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest. The close of this new fund makes it the biggest capital raise by a private-equity company in Asia. (3-0)

Unity Biotechnology Isn't All It's Cracked Up To Be

2018-09-16 seekingalpha
Unity Biotechnology saw strong gains in the market on Thursday after the CEO appeared on CNBC.

Unity (UBX) Catches Eye: Stock Jumps 8.8%

2018-09-14 zacks
Unity Biotechnology, Inc. (UBX - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company — as the stock is now up 28.6% in the past one-month time frame.

R&D Cooperation Between China and Western Pharma Companies Up 70 Percent

2018-09-14 biospace
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.

Longevity Company Unity Biotechnology Stocks Soared After CEO Talks to CNBC

2018-09-14 biospace
After Unity Biotechnology chief executive officer Keith Leonard was on CNBC’s “Power Lunch,” touting the company’s therapeutic approach to longevity and aging, company shares soared almost 18 percent. Trading was halted for volatility, and after it resumed, shares lost some of those gains, eventually ending up about eight percent.

Elevian Launches to Join Numerous Companies Focused on Longevity and Aging

2018-09-10 biospace
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. The funding was from Bold Capital, led by Peter Diamandis, Elevian’s founding investor, WTI, Stanford StartX, Longevity Fund, Kizoo Ventures, Thynk Capital and others.

Here are the 10 disruptive innovations Citi says to put money behind

2018-08-23 cnbc
From anti-aging medicines to new the evolution of esports, Citi Research told clients which technologies it believes are the most disruptive in the world today are and how to invest in them.

AbbVie and Calico Add Additional $1 Billion to 2014 Age-Related Disease Deal

2018-06-27 biospace
Nearly four years after first forging a research collaboration, AbbVie and Calico, Google’s life science company, have extended that 10-year pact with another $1 billion pledge to develop therapies associated with age-related diseases, including neurodegeneration and cancer. (0-1)

Concerns Rise Over Negative Impact of HEV Light on Skin as Companies Delve Into Anti-Aging Therap...

2018-06-22 biospace
Something that most everyone does multiple times a day may not be as care-free as initially thought. Taking a selfie with a smart phone can actually be harmful to your skin.

What’s the Deal with Longevity Company Unity Biotechnology and its $700 Million Valuation?

2018-06-06 biospace
Early biotech company valuations are a type of voodoo made up of interesting ideas, talented management, investor enthusiasm and wishful thinking. How to explain UNITY Biotechnology, which wants to help you stay young until you die? The company has raised $222 million in venture capital, raised $85 million in an initial public offering (IPO) in May, and has a value of $700 million. All without having a product to sell. (0-1)

CUSIP: 91381U101